lifestyle.californiaconsumerbanking.com

Author: Cellectis Inc.

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

May 7, 2026
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

May 6, 2026
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

May 1, 2026